How Much Is Semaglutide in the UK, and What Does the Price Actually Cover?

What NICE and the trial evidence tell us about semaglutide's value

NICE recommended semaglutide (Wegovy) for weight management in March 2023, following results from the STEP 1 trial published in the New England Journal of Medicine: participants on the 2.4 mg weekly dose lost an average of around 15% of body weight over 68 weeks alongside lifestyle changes. That clinical track record underpins why private demand is high, and why the medicine carries the price it does.

The licensed UK product is Wegovy, a once-weekly subcutaneous injection manufactured by Novo Nordisk, available in a titration schedule starting at 0.25 mg and rising, under prescriber supervision, to a 2.4 mg maintenance dose. A higher 7.2 mg dose received MHRA approval in January 2026, with a dedicated single-dose pen approved in April 2026 for adults with a BMI of 30 or above. These approvals have expanded the treatment landscape, and affected how providers price across the dose range.

A question our prescribers hear most weeks is whether the higher doses cost significantly more. The honest answer is: it varies by provider, and if you are unsure how much semaglutide per week you should be taking at each stage, that decision is made clinically, not chosen from a menu. What you pay at any given stage should reflect legitimate medicine sourced through the licensed UK supply chain, dispensed by a pharmacy you can verify on the GPhC register.

Why two providers can quote very different semaglutide prices

Private semaglutide prices in the UK have shifted considerably since Eli Lilly's August 2025 price increase on its competing product, which moved the reference point for the whole injectable weight-loss market. As widely reported at the time, some providers absorbed the change; others passed it on in full or adjusted their service scope.

The more useful question is what a quoted price includes. Many advertised figures cover the pen only. The clinical consultation (without which a prescription cannot legally be issued) may be billed separately, sometimes at £25–£50 per session. Delivery is charged extra by some providers. Aftercare, dose-review calls and follow-up prescriptions can each carry their own fees. Taken together, those additions can push the real monthly outlay well above the headline figure, and understanding the generic semaglutide cost alongside branded options helps put those figures in perspective. The full cost of semaglutide treatment often looks different once those extras are added up.

At nume, one price covers everything: consultation, prescription, treatment and free next-working-day tracked delivery. There are no subscriptions and no auto-renewals. Every repeat order is clinically re-reviewed before it's processed. We are not the cheapest option on the market, and that is a deliberate position, not an oversight. The Wegovy price breakdown page sets out how that works in practice.

How semaglutide is licensed, and why that shapes what you should pay

Semaglutide is a prescription-only medicine under UK law. The weight-loss licence covers Wegovy specifically, not Ozempic, which carries a diabetes licence only, and not Rybelsus tablets in the strengths used for diabetes management. The newer Wegovy tablet (oral semaglutide, 25 mg maintenance dose) received MHRA approval in June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK, though it is not yet available on the NHS and requires a private prescription.

The licensed eligibility threshold is a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber (not a questionnaire or an algorithm) makes the final call, taking your full medical picture into account, including guidance on how much semaglutide to take at each point in your treatment. The Wegovy overview covers the eligibility criteria in full.

For context on what the NHS route looks like, NICE's recommendation under TA875 restricts semaglutide on the NHS to specialist weight management services, with strict BMI and comorbidity criteria and a two-year treatment limit. Most people accessing semaglutide privately do so because they either fall outside those criteria or prefer not to wait for a referral.

Why price is the wrong test for a prescription medicine

The MHRA has warned repeatedly about fake weight-loss pens sold online, including through social media. Counterfeit products seized in the UK have in some cases contained insulin rather than semaglutide, a potentially life-threatening substitution. Large-scale enforcement operations through 2025 resulted in the seizure of tens of millions of pounds' worth of illegally traded weight-loss medicines. Sellers offering semaglutide without a proper clinical assessment, or at prices far below the market rate, are a red flag worth taking seriously. You can report any suspect seller via the MHRA's Yellow Card scheme.

The safest guide to a legitimate source is whether the pharmacy appears on the GPhC register and whether a real prescriber reviews your case before anything is dispensed. At nume, our GPhC premises registration (9012878) is publicly verifiable. Treatment pricing is shown on our treatment page, the right place to start if you'd like our prescribers to assess your suitability. For a broader comparison of what semaglutide costs across different access routes, the how much does semaglutide cost page pulls together the key context.